Mark Heffernan

Mark Heffernan currently serves as the Senior Vice President of Biotherapeutics and CEO of the Ceva Biotechnology Campus in Philadelphia, beginning this role in January 2024. Previously, Mark was the CEO of ScoutBio from August 2018 to January 2024, focusing on AAV gene therapy for chronic diseases in companion animals. Other leadership positions include CEO at Biofactus since August 2017, CEO at Stonehaven Incubate from March 2018 to March 2021, and CEO at Nexvet Biopharma from April 2011 to July 2017, where innovative medicines for companion animals were developed. Mark's career in biotechnology began at Opsona Therapeutics Ltd, where Mark also held the CEO position from 2004 to 2011. Mark earned a PhD in Biochemistry and Molecular Biology from Monash University, where studies were conducted from 1993 to 2000.